These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10828090)

  • 1. Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase. Implications for HDL function.
    Lee M; Uboldi P; Giudice D; Catapano AL; Kovanen PT
    J Lipid Res; 2000 Jun; 41(6):975-84. PubMed ID: 10828090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux.
    Lee M; Calabresi L; Chiesa G; Franceschini G; Kovanen PT
    Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1475-81. PubMed ID: 12231569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma.
    Lee M; von Eckardstein A; Lindstedt L; Assmann G; Kovanen PT
    Arterioscler Thromb Vasc Biol; 1999 Apr; 19(4):1066-74. PubMed ID: 10195937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux.
    Lee M; Kovanen PT; Tedeschi G; Oungre E; Franceschini G; Calabresi L
    J Lipid Res; 2003 Mar; 44(3):539-46. PubMed ID: 12562834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells.
    Lee M; Metso J; Jauhiainen M; Kovanen PT
    J Biol Chem; 2003 Apr; 278(15):13539-45. PubMed ID: 12531890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboxyl-Terminal Cleavage of Apolipoprotein A-I by Human Mast Cell Chymase Impairs Its Anti-Inflammatory Properties.
    Nguyen SD; Maaninka K; Lappalainen J; Nurmi K; Metso J; Öörni K; Navab M; Fogelman AM; Jauhiainen M; Lee-Rueckert M; Kovanen PT
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):274-84. PubMed ID: 26681753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein.
    Favari E; Lee M; Calabresi L; Franceschini G; Zimetti F; Bernini F; Kovanen PT
    J Biol Chem; 2004 Mar; 279(11):9930-6. PubMed ID: 14701812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mast cell-dependent proteolytic modification of HDL particles during anaphylactic shock in the mouse reduces their ability to induce cholesterol efflux from macrophage foam cells ex vivo.
    Judström I; Jukkola H; Metso J; Jauhiainen M; Kovanen PT; Lee-Rueckert M
    Atherosclerosis; 2010 Jan; 208(1):148-54. PubMed ID: 19679305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
    Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
    Biochem J; 2007 Aug; 406(1):167-74. PubMed ID: 17506726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid.
    Lindstedt L; Lee M; Castro GR; Fruchart JC; Kovanen PT
    J Clin Invest; 1996 May; 97(10):2174-82. PubMed ID: 8636396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the surface lipid composition of reconstituted LPA-I on apolipoprotein A-I structure and lecithin: cholesterol acyltransferase activity.
    Sparks DL; Frank PG; Neville TA
    Biochim Biophys Acta; 1998 Feb; 1390(2):160-72. PubMed ID: 9507105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of apolipoprotein A-I lipidation on the formation and function of pre-beta and alpha-migrating LpA-I particles.
    Sparks DL; Frank PG; Braschi S; Neville TA; Marcel YL
    Biochemistry; 1999 Feb; 38(6):1727-35. PubMed ID: 10026251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered epitope expression of human interstitial fluid apolipoprotein A-I reduces its ability to activate lecithin cholesterol acyl transferase.
    Wong L; Curtiss LK; Huang J; Mann CJ; Maldonado B; Roheim PS
    J Clin Invest; 1992 Dec; 90(6):2370-5. PubMed ID: 1281832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein A-IFIN (Leu159-->Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts.
    Miettinen HE; Jauhiainen M; Gylling H; Ehnholm S; Palomäki A; Miettinen TA; Kontula K
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3021-32. PubMed ID: 9409289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mast cell proteases: physiological tools to study functional significance of high density lipoproteins in the initiation of reverse cholesterol transport.
    Lee-Rueckert M; Kovanen PT
    Atherosclerosis; 2006 Nov; 189(1):8-18. PubMed ID: 16530202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The N-terminal globular domain and the first class A amphipathic helix of apolipoprotein A-I are important for lecithin:cholesterol acyltransferase activation and the maturation of high density lipoprotein in vivo.
    Scott BR; McManus DC; Franklin V; McKenzie AG; Neville T; Sparks DL; Marcel YL
    J Biol Chem; 2001 Dec; 276(52):48716-24. PubMed ID: 11602583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states.
    Asztalos BF; Schaefer EJ; Horvath KV; Yamashita S; Miller M; Franceschini G; Calabresi L
    J Lipid Res; 2007 Mar; 48(3):592-9. PubMed ID: 17183024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers.
    Daum U; Leren TP; Langer C; Chirazi A; Cullen P; Pritchard PH; Assmann G; von Eckardstein A
    J Lipid Res; 1999 Mar; 40(3):486-94. PubMed ID: 10064737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chymase released from hypoxia-activated cardiac mast cells cleaves human apoA-I at Tyr
    Kareinen I; Baumann M; Nguyen SD; Maaninka K; Anisimov A; Tozuka M; Jauhiainen M; Lee-Rueckert M; Kovanen PT
    J Lipid Res; 2018 Jun; 59(6):945-957. PubMed ID: 29581158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-directed mutagenesis and structure-function analysis of the human apolipoprotein A-I. Relation between lecithin-cholesterol acyltransferase activation and lipid binding.
    Minnich A; Collet X; Roghani A; Cladaras C; Hamilton RL; Fielding CJ; Zannis VI
    J Biol Chem; 1992 Aug; 267(23):16553-60. PubMed ID: 1644835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.